ArticleJournal of translational medicine2026
A novel therapeutic monoclonal antibody targeting PZR demonstrates potent anti-metastatic efficacy in triple-negative breast cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastasis is the leading cause of mortality in triple-negative breast cancer (TNBC). PZR, a member of the immunoglobulin super-family, promotes the migration, invasion, and metastasis of cancer cells. Whether targeting PZR can inhibit TNBC dissemination remains unclear. In this study, we developed a novel anti-PZR monoclonal antibody (mAb) and humanized it to explore its impact on TNBC metastasis.
methodsRecombinant PZR-ECD protein was used to generate anti-PZR monoclonal antibodies, whose binding affinity was evaluated by SPR. Their effects on cell migration were assessed via Trans-well assays. Antibody specificity was confirmed by western blotting, Co-IP, and FACS. PZR mediated TNBC cell interactions with the ECM were examined through cell adhesion experiments. The therapeutic efficacy of the PZR antibody was evaluated in a TNBC metastasis mouse model.
resultsOur findings revealed that the mouse anti-PZR mAb (12F6) exhibited high-affinity binding to the recombinant PZR protein. The 12F6 mAb specifically recognized the native PZR protein expressed by TNBC cells and was efficiently internalized by PZR-positive TNBC cells. Furthermore, 12F6 significantly inhibited the migration and metastasis of PZR-positive TNBC cells in both in vitro and in vivo settings. PZR was found to interact with integrin β1, promoting the fibronectin-dependent adhesion and FAK activation of TNBC cells. The humanized 12F6 antibody (Hu12F6) maintained comparable binding affinity to PZR in comparison with the parental 12F6 antibody and effectively inhibited the migration and metastasis of PZR-positive TNBC cells in both in vitro and in vivo experiments.
conclusionsThe results of our study support a model by which PZR interacting with integrin β1 enhances fibronectin-dependent integrin signaling and biological functions. Hu12F6 by blocking the interaction between PZR and integrin β1 may offer a novel therapeutic strategy to treat PZR-positive metastatic cancers including TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.